The GOLD guidelines provide evidence-based strategies for the diagnosis and management of COPD. The GOLD 2025 update has refined the sections on diagnosis and management of COPD and reflects on the latest evidence on newly recommended therapies.
_COPD.png)
The article "Biomarkers to guide COPD management" features insights from a round table discussion involving leading respiratory experts. It focuses on chronic obstructive pulmonary disease (COPD), a heterogeneous and progressive condition. The experts discuss the risk factors for frequent exacerbation, use of blood eosinophil count (EOS) as a biomarker in COPD, and the association of EOS with type 2 inflammation.
_COPD.png)
The article "How do different inflammatory pathways in COPD impact disease pathobiology and progression?" features insights from a round table discussion involving leading respiratory experts. It focuses on chronic obstructive pulmonary disease (COPD), a heterogeneous and progressive condition. The experts delved into the inflammatory processes in COPD, particularly type 2 pathway and its associated endotype, emphasizing the importance of identifying patients by endotypes.
_COPD.png)
In a roundtable chaired by Professor Paola Rogliani, Dr. Marc Miravitlles highlighted the need for personalized COPD therapies, improved diagnostics, and greater awareness of non-smoking risk factors to better manage exacerbations and disease progression.
This article highlights the stability and predictive value of blood eosinophil levels in COPD, showing their strong link to exacerbation risk. Consistently elevated eosinophil levels can guide personalized treatment, including early use of inhaled corticosteroids (ICS). Integrating eosinophil measurements into routine practice can improve long-term disease management and patient outcomes.
Exacerbations are key events in COPD1 that play a crucial role in disease progression. Although often managed in outpatient settings, exacerbations contribute significantly to the overall burden of COPD.2 These events are characterized by an acute worsening of respiratory symptoms, including increased dyspnea associated with cough and production of purulent sputum, increased wheezing and chest discomfort.1,3 These characteristics reflect an underlying inflammatory response2 that exacerbates the disease process.
Chronic Obstructive Pulmonary Disease (COPD) is typically suspected in patients with symptoms like dyspnea, chronic cough, or sputum production. Accurate diagnosis is crucial for effective management, with spirometry being essential for confirmation. Distinguishing COPD from similar conditions, such as asthma, is challenging yet vital. This article provides clear guidance on differentiating COPD from asthma and highlights key tools like spirometry and validated questionnaires for monitoring disease progression and guiding treatment. Understanding and applying these tools can significantly enhance patient outcomes in COPD management.
COPD and asthma are lung diseases marked by airway inflammation. Uncover differences and overlaps in COPD and asthma, including causes, symptoms, and treatment.
Acute COPD exacerbations are linked to significant disease progression. Uncover criteria, symptoms, and treatment guidance to manage them in your patients.